50. 皮膚筋炎／多発性筋炎 Dermatomyositis Clinical trials / Disease details

臨床試験数 : 182 / 薬物数 : 229 - (DrugBank : 88) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 147

diseases per page:

Showing 1 to 10 of 182 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04972760 (ClinicalTrials.gov)	May 2022	14/6/2021	Baricitinib in Patients With Relapsing or naïve Dermatomyositis	Baricitinib in Patients With Relapsing or naïve Dermatomyositis: a Multicenter Randomized Controlled ...	Dermatomyositis	Drug: Baricitinib;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	18 Years	74 Years	All	62	Phase 3	France
2	EUCTR2021-004787-10-HU (EUCTR)	07/03/2022	29/12/2021	An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent S ...	AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO AD ...	Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;Sy ...	Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive ...	Pfizer Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	United States;Hungary;Spain;Poland;Australia;Germany;Italy
3	NCT05239702 (ClinicalTrials.gov)	February 28, 2022	1/12/2021	Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases	A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells ...	Crohn Disease;Ulcerative Colitis;Dermatomyositis;Still Disease;Autoimmune Diseases	Biological: CD7 CAR T-cells	Zhejiang University	Yake Biotechnology Ltd.	Recruiting	N/A	N/A	All	75	Early Phase 1	China
4	EUCTR2021-004787-10-PL (EUCTR)	31/01/2022	05/01/2022	An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent S ...	AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO AD ...	Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;Sy ...	Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive ...	Pfizer Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	United States;Hungary;Spain;Poland;Australia;Germany;Italy
5	NCT05192200 (ClinicalTrials.gov)	December 20, 2021	1/12/2021	An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent S ...	AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO AD ...	Dermatomyositis	Drug: Anti-Beta Interferon (PF-06823859)	Pfizer	NULL	Recruiting	18 Years	80 Years	All	30	Phase 2	United States
6	NCT04999020 (ClinicalTrials.gov)	December 2, 2021	4/8/2021	Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis	A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Eval ...	Dermatomyositis	Drug: Ravulizumab;Drug: Placebo	Alexion Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	180	Phase 2/Phase 3	United States;France;Germany;Italy;Korea, Republic of;Spain
7	EUCTR2021-000898-83-IT (EUCTR)	10/11/2021	07/10/2021	Phase II placebo controlled study, to evaluate the efficacy and safety of begelomab in combination w ...	A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the ...	Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;Sy ...	Product Name: Begelomab Product Code: [Not applicable]	ADIENNE SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Italy
8	NCT04723303 (ClinicalTrials.gov)	October 6, 2021	8/12/2020	Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)	Phase 1 Study of Mesenchymal Stromal Cells, Umbilical Cord Lining Stem Cells (ULSC), in Patients Wit ...	Polymyositis;Dermatomyositis	Drug: Umbilical Cord Lining Stem Cells	University of Florida	Restem, LLC.	Recruiting	18 Years	90 Years	All	22	Early Phase 1	United States
9	EUCTR2021-001200-15-DE (EUCTR)	05/10/2021	15/06/2021	Ravulizumab versus Placebo in Adult Participants with Dermatomyositis.	A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Eval ...	Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;Sy ...	Trade Name: Ultomiris Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: RAVULIZUMAB ...	Alexion Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 2;Phase 3	France;United States;Spain;Germany;United Kingdom;Italy;Japan;Korea, Republic of
10	EUCTR2021-001200-15-ES (EUCTR)	27/09/2021	16/09/2021	Ravulizumab versus Placebo in Adult Participants with Dermatomyositis.	A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Eval ...	Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;Sy ...	Trade Name: Ultomiris Product Name: Ravulizumab Product Code: ALXN1210 INN or Proposed INN: RAVULIZUMAB ...	Alexion Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 2;Phase 3	France;United States;Spain;Germany;United Kingdom;Italy;Japan;Korea, Republic of

First Previous1 2 3 4 5…19Next Last